Seres therapeutics reports second quarter 2022 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported second quarter 2022 financial results and provided business updates. “we made considerable progress on key clinical, corporate and commercial initiatives that bolster our leadership in the microbiome field,” said eric shaff, president and chief executive officer at seres. “we were delighted to report positive confirmatory safety and efficacy data from our ser-109
MCRB Ratings Summary
MCRB Quant Ranking